Changing the Antipsychotic in Early Nonimprovers to Amisulpride or Olanzapine: Randomized, Double-Blind Trial in Patients With Schizophrenia.
Stephan HeresJoachim CordesSandra FeyerabendChristian Schmidt-KraepelinRichard MusilMichael RiedelIlja SpellmannBerthold LangguthMichael LandgrebeElmar FranCamelia Petcu CEric HahnTam M T TaValentin MateiLiana DeheleanIon PapavaF Markus LewekeTill van der ListSimona C TamasanFabian U LangDieter NaberStephan RuhrmannClaus Wolff-MenzlerGeorg JuckelMaria LadeaCristinel StefanescuMarion LautenschlagerMichael BauerDaisy ZamoraMark S HorowitzJohn M DavisStefan LeuchtPublished in: Schizophrenia bulletin (2022)
Switching "non-improvers" from amisulpride to olanzapine or vice-versa increased remission rates and was safe. The superiority in the primary outcome was, however, not paralleled by significant differences in most secondary efficacy outcomes and the effect was only apparent at the last visit making replications of longer duration necessary.